GTBP
GT Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.16
−4.41%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$7.52
From 52W high−73.48%
Volume37459.00
Market cap$12.92M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$7.52
From 52W high
−73.48%
Volume
37459.00
Market cap
$12.92M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
P/E (TTM)
—
RSI (14)
48.3
MomentumView details →
1D Return
−4.41%
YTD Return
−62.71%
SummaryUpdated Jun 1, 2026
GT Biopharma, Inc. (NASDAQ:GTBP) is a clinical-stage biopharmaceutical company founded in 1965 and headquartered in Brisbane, California. Originally incorporated as OXIS International, Inc., the company underwent a strategic transformation and rebranded to GT Biopharma in July 2017 to focus on developing innovative cancer immunotherapies. The company specializes in immuno-oncology treatments based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein technology platform, with multiple drug candidates currently in clinical and preclinical development stages.
Similar companies
Latest newsMore news →
GT Biopharma received FDA clearance of a new IND for GTB-5550 in multiple myeloma under an investigator-sponsored trial protocol.5d agoGT Biopharma, Inc. directors and officers signed a Lock-Up Agreement not to sell or transfer any securities of the Company until 30 days after the later of the Effective Date and the date Shareholder Approval is obtained.5d agoGT Biopharma, Inc. officers and directors signed a Voting Agreement to vote all shares of voting stock under their control in favor of a proposal seeking Shareholder Approval for issuance of more than 19.99% of the Company's outstanding Common Stock.5d ago